MediWound (NASDAQ:MDWD) Shares Pass Below Two Hundred Day Moving Average – Here’s Why

MediWound Ltd. (NASDAQ:MDWD)’s stock price crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $17.40 and traded as low as $16.05. MediWound shares last traded at $16.29, with a volume of 28,922 shares changing hands.

Analysts Set New Price Targets

A number of research analysts have issued reports on MDWD shares. Craig Hallum assumed coverage on MediWound in a research report on Friday, February 28th. They issued a “buy” rating and a $39.00 target price on the stock. StockNews.com upgraded MediWound to a “sell” rating in a research note on Friday, March 21st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $25.00 price target on shares of MediWound in a research report on Thursday, March 20th.

MediWound Stock Performance

The company’s 50-day moving average is $16.93 and its 200 day moving average is $17.39. The company has a market capitalization of $184.82 million, a PE ratio of -5.90 and a beta of 0.50.

MediWound (NASDAQ:MDWD) last announced its quarterly earnings data on Wednesday, March 19th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.23. The firm had revenue of $5.84 million during the quarter, compared to analysts’ expectations of $5.79 million. MediWound had a negative net margin of 142.29% and a negative return on equity of 82.17%. During the same period in the prior year, the company posted ($0.19) earnings per share. On average, analysts forecast that MediWound Ltd. will post -2.66 EPS for the current fiscal year.

Institutional Investors Weigh In On MediWound

Large investors have recently modified their holdings of the business. State Street Corp grew its position in MediWound by 219.6% during the third quarter. State Street Corp now owns 66,258 shares of the biopharmaceutical company’s stock valued at $1,197,000 after buying an additional 45,529 shares during the period. Barclays PLC lifted its stake in shares of MediWound by 311.3% in the 3rd quarter. Barclays PLC now owns 11,163 shares of the biopharmaceutical company’s stock valued at $202,000 after purchasing an additional 8,449 shares during the last quarter. Rhumbline Advisers raised its position in MediWound by 7.3% in the fourth quarter. Rhumbline Advisers now owns 10,835 shares of the biopharmaceutical company’s stock valued at $193,000 after purchasing an additional 739 shares during the period. Essex Investment Management Co. LLC lifted its position in shares of MediWound by 30.7% during the fourth quarter. Essex Investment Management Co. LLC now owns 148,949 shares of the biopharmaceutical company’s stock worth $2,651,000 after purchasing an additional 35,012 shares in the last quarter. Finally, R Squared Ltd acquired a new stake in MediWound in the 4th quarter valued at about $32,000. Hedge funds and other institutional investors own 46.83% of the company’s stock.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.